Investment Thesis
Aethlon Medical is in severe financial distress with minimal revenue generation ($97.1K) while burning significant cash (-$5.2M operating cash flow). The company is unprofitable with negative net margins exceeding -5400%, operating margins of -5523%, and deteriorating returns on equity (-78.5%) and assets (-65.4%). Despite adequate liquidity currently, the company's burn rate will exhaust cash reserves within 16 months without revenue acceleration or capital injection.
Strengths
- Strong liquidity position with cash-to-assets ratio of 86% and current ratio of 5.68x
- Zero long-term debt provides financial flexibility and no refinancing risk
- Minimal capital expenditure requirements suggest asset-light business model
Risks
- Critical revenue shortfall with only $97.1K in annual revenue indicating failed market traction or commercialization
- Severe cash burn of $5.2M annually will deplete $7.0M cash reserves in approximately 16 months without intervention
- Deeply unprofitable operations with -$11.01 diluted EPS and no clear path to profitability based on current business execution
- Negative returns on equity (-78.5%) and assets (-65.4%) indicate shareholder capital destruction
- Operating losses of -$5.4M dwarf minimal revenue, suggesting fundamental business model failure
Key Metrics to Watch
- Quarterly revenue growth and pipeline development indicators
- Monthly cash burn rate and runway remaining before capital depletion
- Operating expense reduction initiatives and path to cash flow breakeven
- Clinical trial progress or FDA approvals for core therapeutic platforms
- Insider trading activity pattern and confidence signals from management
Financial Metrics
Revenue
97.1K
Net Income
-5.3M
EPS (Diluted)
$-11.01
Free Cash Flow
-5.2M
Total Assets
8.1M
Cash
7.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-5,522.7%
Net Margin
-5,422.7%
ROE
-78.5%
ROA
-65.4%
FCF Margin
-5,404.7%
Balance Sheet & Liquidity
Current Ratio
5.68x
Quick Ratio
5.68x
Debt/Equity
0.00x
Debt/Assets
16.7%
Interest Coverage
-530.65x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T15:04:16.366679 |
Data as of: 2025-12-31 |
Powered by Claude AI